BTX306

BTX306 (72 h) shows potent anti-proliferation activity against myeloma cell lines with IC₅₀s in the single nanomolar range, including H929, MM1.S, RPMI 8226, and KAS-6/1 cells^[1].
BTX306 (1-10 nM, 12 h) induces cleavage of caspase-3, -8, and -9, indicating that it triggers apoptosis in H929, MM1.S, RPMI 8226, and KAS-6/1 cells^[1].
BTX306 (0-10 nM, 24 h) rapidly reduces levels of GSPT1, and also of eukaryotic release factor 1 (eRF1), casein kinase 1 α (CK1α), myeloid cell leukemia 1 (MCL-1), and the eukaryotic homolog of the V-Myc avian myelocytomatosis viral oncogene (c-MYC) in MM1.S, MOLP-8, H929, U266, RPMI 8226, and KAS-6/1 cells^[1].
BTX306 (0-10 nM) efficiently eliminates human cord blood CD34⁺ cells while sparing murine hematopoietic cells, and exerts its effects on RPMI 8226 and MM1.S myeloma cell viability in a cereblon-dependent manner, confirming its specificity for human cereblon^[1].
BTX306 (0.01-65.61 nM, 3 days) exhibits potent activity against Lenalidomide-resistant, Bortezomib-resistant, and p53 knockout myeloma models in diverse cell lines (including MM1.S, MOLP-8, H929, U266, RPMI 8226, ANBL-6, and KAS-6/1)^[1].
BTX306 potently reduces primary myeloma (CD138⁺ plasma cells) cell viability, and it shows a greater cell viability reduction in MM1.S and KAS-6/1 cells when combined with Bortezomib or Dexamethasone (HY-14648)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.